Literature DB >> 30792203

Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.

Ali Bazarbachi1,2, Myriam Labopin3,4,5, Giorgia Battipaglia4,6, Azedine Djabali3,4, Jakob Passweg7, Gerard Socié8, Edouard Forcade9, Didier Blaise10, Patrice Chevallier11, Corentin Orvain12, Jan J Cornelissen13, William Arcese14, Sylvain Chantepie15, Khowla Hashaishi3, Jean El Cheikh16, Michael Medinger7, Jordi Esteve3,17, Arnon Nagler3,18, Mohamad Mohty3,4,5.   

Abstract

Entities:  

Year:  2019        PMID： 30792203      PMCID： PMC6717576          DOI： 10.3324/haematol.2018.211615

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.

Authors:  J Winkler; D Rech; S Kallert; J Rech; N Meidenbauer; W Roesler; A Mackensen
Journal:  Leuk Res       Date:  2010-06-02       Impact factor: 3.156

2.  Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Authors:  Andrew M Brunner; Shuli Li; Amir T Fathi; Martha Wadleigh; Vincent T Ho; Kerry Collier; Christine Connolly; Karen K Ballen; Corey S Cutler; Bimalangshu R Dey; Areej El-Jawahri; Sarah Nikiforow; Steven L McAfee; John Koreth; Daniel J Deangelo; Edwin P Alyea; Joseph H Antin; Thomas R Spitzer; Richard M Stone; Robert J Soiffer; Yi-Bin Chen
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

3.  Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Authors:  Martin Bornhäuser; Thomas Illmer; Markus Schaich; Silke Soucek; Gerhard Ehninger; Christian Thiede
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

4.  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Authors:  Nimitha R Mathew; Francis Baumgartner; Lukas Braun; David O'Sullivan; Simone Thomas; Miguel Waterhouse; Tony A Müller; Kathrin Hanke; Sanaz Taromi; Petya Apostolova; Anna L Illert; Wolfgang Melchinger; Sandra Duquesne; Annette Schmitt-Graeff; Lena Osswald; Kai-Li Yan; Arnim Weber; Sonia Tugues; Sabine Spath; Dietmar Pfeifer; Marie Follo; Rainer Claus; Michael Lübbert; Christoph Rummelt; Hartmut Bertz; Ralph Wäsch; Johanna Haag; Andrea Schmidts; Michael Schultheiss; Dominik Bettinger; Robert Thimme; Evelyn Ullrich; Yakup Tanriver; Giang Lam Vuong; Renate Arnold; Philipp Hemmati; Dominik Wolf; Markus Ditschkowski; Cordula Jilg; Konrad Wilhelm; Christian Leiber; Sabine Gerull; Jörg Halter; Claudia Lengerke; Thomas Pabst; Thomas Schroeder; Guido Kobbe; Wolf Rösler; Soroush Doostkam; Stephan Meckel; Kathleen Stabla; Stephan K Metzelder; Sebastian Halbach; Tilman Brummer; Zehan Hu; Joern Dengjel; Björn Hackanson; Christoph Schmid; Udo Holtick; Christof Scheid; Alexandros Spyridonidis; Friedrich Stölzel; Rainer Ordemann; Lutz P Müller; Flore Sicre-de-Fontbrune; Gabriele Ihorst; Jürgen Kuball; Jan E Ehlert; Daniel Feger; Eva-Maria Wagner; Jean-Yves Cahn; Jacqueline Schnell; Florian Kuchenbauer; Donald Bunjes; Ronjon Chakraverty; Simon Richardson; Saar Gill; Nicolaus Kröger; Francis Ayuk; Luca Vago; Fabio Ciceri; Antonia M Müller; Takeshi Kondo; Takanori Teshima; Susan Klaeger; Bernhard Kuster; Dennis Dong Hwan Kim; Daniel Weisdorf; Walter van der Velden; Daniela Dörfel; Wolfgang Bethge; Inken Hilgendorf; Andreas Hochhaus; Geoffroy Andrieux; Melanie Börries; Hauke Busch; John Magenau; Pavan Reddy; Myriam Labopin; Joseph H Antin; Andrea S Henden; Geoffrey R Hill; Glen A Kennedy; Merav Bar; Anita Sarma; Donal McLornan; Ghulam Mufti; Betul Oran; Katayoun Rezvani; Omid Shah; Robert S Negrin; Arnon Nagler; Marco Prinz; Andreas Burchert; Andreas Neubauer; Dietrich Beelen; Andreas Mackensen; Nikolas von Bubnoff; Wolfgang Herr; Burkhard Becher; Gerard Socié; Michael A Caligiuri; Eliana Ruggiero; Chiara Bonini; Georg Häcker; Justus Duyster; Jürgen Finke; Erika Pearce; Bruce R Blazar; Robert Zeiser
Journal:  Nat Med       Date:  2018-02-12       Impact factor: 53.440

5.  Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

Authors:  Manish Sharma; Farhad Ravandi; Ulas Darda Bayraktar; Alexandre Chiattone; Qaiser Bashir; Sergio Giralt; Julianne Chen; Muzaffar Qazilbash; Partow Kebriaei; Marina Konopleva; Michael Andreeff; Jorge Cortes; Deborah McCue; Hagop Kantarjian; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-20       Impact factor: 5.742

6.  Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Authors:  Yi-Bin Chen; Shuli Li; Andrew A Lane; Christine Connolly; Candice Del Rio; Betsy Valles; Morgan Curtis; Karen Ballen; Corey Cutler; Bimalangshu R Dey; Areej El-Jawahri; Amir T Fathi; Vincent T Ho; Amy Joyce; Steven McAfee; Michelle Rudek; Trivikram Rajkhowa; Sigitas Verselis; Joseph H Antin; Thomas R Spitzer; Mark Levis; Robert Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-17       Impact factor: 5.742

7.  Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Ahmad Antar; Mohamed A Kharfan-Dabaja; Rami Mahfouz; Ali Bazarbachi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-12

8.  Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Authors:  Giorgia Battipaglia; Annalisa Ruggeri; Radwan Massoud; Jean El Cheikh; Matthieu Jestin; Ahmad Antar; Syed Osman Ahmed; Walid Rasheed; Marwan Shaheen; Ramdane Belhocine; Eolia Brissot; Remy Dulery; Sandra Eder; Federica Giannotti; Francoise Isnard; Simona Lapusan; Marie-Therese Rubio; Anne Vekhoff; Mahmoud Aljurf; Ollivier Legrand; Mohamad Mohty; Ali Bazarbachi
Journal:  Cancer       Date:  2017-04-07       Impact factor: 6.860

9.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.

Authors:  Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

10.  Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.

Authors:  S K Metzelder; T Schroeder; M Lübbert; M Ditschkowski; K Götze; S Scholl; R G Meyer; P Dreger; N Basara; M F Fey; H R Salih; A Finck; T Pabst; A Giagounidis; G Kobbe; E Wollmer; J Finke; A Neubauer; A Burchert
Journal:  Eur J Cancer       Date:  2017-10-18       Impact factor: 9.162
View more
  15 in total

Review 1.  Current Approaches to Transplantation for FLT3-ITD AML.

Authors:  Bradley D Hunter; Yi-Bin Chen
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 2.  Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant.

Authors:  Abdul Hamid Bazarbachi; Rama Al Hamed; Florent Malard; Mohamad Mohty; Ali Bazarbachi
Journal:  Ther Adv Hematol       Date:  2019-11-01

Review 3.  Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

Authors:  Motoki Eguchi; Yosuke Minami; Ayumi Kuzume; Sunggi Chi
Journal:  Biomedicines       Date:  2020-07-24

4.  TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Nico Gagelmann; Christine Wolschke; Evgeny Klyuchnikov; Maximilian Christopeit; Francis Ayuk; Nicolaus Kröger
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

Review 5.  Treatment of AML Relapse After Allo-HCT.

Authors:  Jonathan A Webster; Leo Luznik; Ivana Gojo
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 6.  Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Ali Bazarbachi; Gesine Bug; Frederic Baron; Eolia Brissot; Fabio Ciceri; Iman Abou Dalle; Hartmut Döhner; Jordi Esteve; Yngvar Floisand; Sebastian Giebel; Maria Gilleece; Norbert-Claude Gorin; Elias Jabbour; Mahmoud Aljurf; Hagop Kantarjian; Mohamed Kharfan-Dabaja; Myriam Labopin; Francesco Lanza; Florent Malard; Zinaida Peric; Thomas Prebet; Farhad Ravandi; Annalisa Ruggeri; Jaime Sanz; Christoph Schmid; Roni Shouval; Alexandros Spyridonidis; Jurjen Versluis; Norbert Vey; Bipin N Savani; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941

Review 7.  Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Wei Shi; Weiwei Jin; Linghui Xia; Yu Hu
Journal:  Acta Pharm Sin B       Date:  2020-06-30       Impact factor: 11.413

Review 8.  The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation.

Authors:  Iman Abou Dalle; Ali Atoui; Ali Bazarbachi
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

9.  Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.

Authors:  Lubomír Minařík; Kristýna Pimková; Juraj Kokavec; Adéla Schaffartziková; Fréderic Vellieux; Vojtěch Kulvait; Lenka Daumová; Nina Dusilková; Anna Jonášová; Karina Savvulidi Vargová; Petra Králová Viziová; Radislav Sedláček; Zuzana Zemanová; Tomáš Stopka
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

10.  Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.

Authors:  Qingyu Xu; Shujiao He; Li Yu
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.